Increased TNF-α and interleukine-6 (IL-6) levels through metabolic control exist in types 1 and 2 diabetic patients, which suggest that the control of diabetes improves the capacity of activation and maintenance of these pro-inflammatory cytokines [52–54]. The gene discussed is IL6; the disease is diabetes mellitus.